18 AI News and Ratings Making Waves on Wall Street

Page 6 of 16

11. Tempus AI, Inc. (NASDAQ:TEM)

Number of Hedge Fund Holders: 17

Tempus AI, Inc. (NASDAQ:TEM) provides AI-driven healthcare solutions, including genomic testing, clinical data analysis, and clinical trial matching.

On February 24, TipRanks reported that TD Cowen analyst Daniel Brennan reaffirmed a Buy rating on Tempus AI (NASDAQ:TEM) with a $74 price target. His outlook is based on the company’s strong growth potential, with 2025 revenue guidance exceeding prior expectations. Despite lower genomic volumes, Tempus AI benefits from strong pricing in its AI-powered Insights business and plans to shift genomic testing to a higher-priced FDA-approved assay. The company’s recent sales team expansion further supports future growth. Although EBITDA margin guidance for 2025 is slightly below estimates, the overall financial outlook remains positive.

Page 6 of 16